Insulin resistance
Insulin resistance is the most common yet most under-tested metabolic condition today. It develops 10–20 years before type 2 diabetes and is an independent risk factor for cardiovascular disease, Alzheimer’s, PCOS, fatty liver, and several cancers.
- Develops 5–10 years before glucose rises
- Routine bloodwork (glucose, HbA1c) does not rule it out
- Reversible – if caught early enough

What is insulin resistance?
Insulin is a hormone released by the pancreas after meals. Its job is to move glucose from blood into cells – mainly muscle, liver, and fat tissue. When cells stop responding normally, insulin resistance sets in.
To compensate, the pancreas releases more and more insulin. This state – compensatory hyperinsulinaemia – can last 10–20 years before glucose starts to rise. That is why ‘normal blood sugar’ is far from a guarantee of metabolic health.
Kraft, and later Crofts & Schofield (BMJ Open Diabetes 2016), showed that up to 75% of adults with ‘normal glucose’ have hyperinsulinaemia – missed unless insulin is actually measured.
Signs worth noticing
- Fat around the waist – over 94 cm in men, over 80 cm in women (measure in the morning, at navel level)
- Strong sugar cravings, especially in the afternoon and evening
- Energy drops 2–3 hours after eating; sleepiness after lunch
- Hard to concentrate, a foggy head after bread, pasta or sweets
- Weight won’t move even though you eat less
- Dark velvety patches on the neck or under the arms (doctors call this acanthosis nigricans)
- In women: irregular periods, polycystic ovary syndrome (PCOS), trouble conceiving
- Blood test shows a triglyceride to ‘good cholesterol’ (HDL) ratio above 1.5
Read the full article
Enter your email and the full text opens right here on this page.
Insulin resistance webinars
Recorded sessions ‘Insulin resistance in clinical practice’ and ‘Insulin resistance in women’ – Dr Saadi’s own clinical view, with lab interpretation and practical steps.
HOMA-IR, insulin and glucose norms
Practical lab values for adults (non-pregnant, non-diabetic)
| Marker | Optimal | Borderline | Insulin resistant |
|---|---|---|---|
| HOMA-IR | < 1.0 | 1.0–2.5 | > 2.5 |
| Fasting insulin | < 6 µU/ml | 6–10 µU/ml | > 10 µU/ml |
| Fasting glucose | 4.4–5.0 mmol/l | 5.1–5.6 mmol/l | > 5.6 mmol/l |
| HbA1c | < 5.3 % | 5.4–5.6 % | ≥ 5.7 % |
| Triglycerides / HDL | < 1.5 | 1.5–2.5 | > 2.5 |
| Waist (M / F) | < 94 / 80 cm | 94–102 / 80–88 cm | > 102 / 88 cm |
HOMA-IR
- Optimal
- < 1.0
- Borderline
- 1.0–2.5
- Insulin resistant
- > 2.5
Fasting insulin
- Optimal
- < 6 µU/ml
- Borderline
- 6–10 µU/ml
- Insulin resistant
- > 10 µU/ml
Fasting glucose
- Optimal
- 4.4–5.0 mmol/l
- Borderline
- 5.1–5.6 mmol/l
- Insulin resistant
- > 5.6 mmol/l
HbA1c
- Optimal
- < 5.3 %
- Borderline
- 5.4–5.6 %
- Insulin resistant
- ≥ 5.7 %
Triglycerides / HDL
- Optimal
- < 1.5
- Borderline
- 1.5–2.5
- Insulin resistant
- > 2.5
Waist (M / F)
- Optimal
- < 94 / 80 cm
- Borderline
- 94–102 / 80–88 cm
- Insulin resistant
- > 102 / 88 cm
Ranges based on IDF 2005 metabolic syndrome criteria and Dr Saadi’s clinical practice.
Frequently asked questions
Go deeper: related material
Articles
Related topics
Metabolic health is interconnected – explore the other deep-dives:
Overweight
Why calorie counting fails – hormones, insulin, leptin and adipose tissue.
ReadVagus nerve
The rest-and-repair system – digestion, heart, inflammation, stress.
ReadCholesterol & ApoB
Expanded lipid panel – ApoB, Lp(a), homocysteine, A vs B phenotype.
ReadSleep
The foundation of metabolic health – hormones, cortisol, insulin, brain recovery.
ReadChronic inflammation
The ‘silent fire’ behind cardiovascular disease, diabetes and autoimmunity.
ReadLow-carb and keto
Carbohydrate restriction – IR, T2D, fatty liver, metabolic syndrome.
ReadAgeing
Glycation, insulin, inflammation and muscle – what you can influence yourself.
ReadScientific references
- DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care, 2009. doi.org/10.2337/dc09-S302
- Matthews DR et al. Homeostasis model assessment: insulin resistance and beta-cell function. Diabetologia, 1985. pubmed.ncbi.nlm.nih.gov/3899825/
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988. pubmed.ncbi.nlm.nih.gov/3056758/
- Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiological Reviews, 2018. doi.org/10.1152/physrev.00063.2017
- Spiegel K et al. Impact of sleep debt on metabolic and endocrine function. Lancet, 1999. pubmed.ncbi.nlm.nih.gov/10543671/
- Sutton EF et al. Early time-restricted feeding improves insulin sensitivity. Cell Metabolism, 2018. doi.org/10.1016/j.cmet.2018.04.010
- Volek JS et al. Carbohydrate restriction improves the atherogenic profile in metabolic syndrome. Lipids, 2009. pubmed.ncbi.nlm.nih.gov/19082851/
- Sattar N, Preiss D. HbA1c in metabolic syndrome and prediabetes. Diabetologia, 2019. doi.org/10.1007/s00125-018-4767-z
Dr Sergey Saadi – insulin resistance specialist in Estonia
Dr Sergey Saadi is a physician with more than 15 years of clinical practice.
- Daily clinical work in insulin resistance and metabolic health
- Author of ‘Dangerous secrets of blood sugar’ (Varrak, EST · RU)
- Clinical approach: HOMA-IR + Kraft insulin test + lifestyle audit
- Regular media presence and educator to other physicians
This page is educational and general in nature. It is not personal medical advice, a diagnosis, or a treatment plan. Consult your physician before changing your lifestyle, medications, or supplements.